Mowel (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mowel, is an antimetabolite immunosuppressant presented as an oral tablet formulation for oral administration. It is used to prevent acute and chronic organ transplant rejection and to treat lupus nephritis, helping to control immune‑mediated damage in adult patients.

GNH USA supplies Mowel as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, transplant centres, pharmacies and clinical procurement teams across global markets while adhering to stringent quality and regulatory standards through continuous monitoring.

Mowel (mycophenolate mofetil) acts on the immune system to inhibit lymphocyte proliferation, making it valuable in transplant and autoimmune disease management.

Organ transplant rejection: prevents acute and chronic rejection after kidney, heart, liver or lung transplantation. Lupus nephritis: reduces renal inflammation and proteinuria in patients with systemic lupus erythematosus. Maintenance therapy post‑transplant: supports long‑term graft survival as part of combination immunosuppressive regimens.

Mycophenolate mofetil may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Vomiting - Headache

Serious or Rare Side Effects: - Bone marrow suppression (leukopenia, anemia, thrombocytopenia) - Hepatotoxicity (elevated liver enzymes, hepatitis) - Progressive multifocal leukoencephalopathy (PML)

When prescribing Mowel, clinicians should observe several safety precautions to minimize risk. - Monitor blood counts: perform regular complete blood count tests to detect leukopenia or anemia. - Monitor liver function: assess hepatic enzymes periodically for signs of hepatotoxicity. - Avoid use in pregnancy: the drug is contraindicated (Category X) due to teratogenic risk. - Use effective contraception: both male and female patients must employ reliable birth control during treatment and for several weeks after discontinuation. - Adjust dose in renal impairment: reduce dosage in patients with reduced creatinine clearance as advised by the prescriber. - Store below 25°C: keep in the original packaging, protect from moisture and heat.

Mycophenolate mofetil interacts with several medicines, requiring careful management.

Major Interactions (Avoid): - Live vaccines: may cause severe infection; avoid concurrent administration. - Antacids containing aluminum or magnesium: reduce mycophenolate absorption; separate dosing by at least 2 hours. - Azathioprine: additive bone‑marrow suppression; avoid combined use. - Ribavirin: increased risk of hematologic toxicity; avoid co‑administration. - Cyclosporine or tacrolimus: may raise mycophenolate levels, requiring dose adjustment.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor renal function and potassium levels. - NSAIDs: may worsen renal impairment; assess kidney function regularly.